• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European geriatric medicine. >P-513: Anticholinergic medications in memory clinic attendees
【24h】

P-513: Anticholinergic medications in memory clinic attendees

机译：P-513：记忆诊所与会者中的抗胆碱能药物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Medications with anticholinergic properties are in widespread use. Cumulative anticholinergic exposure (anticholinergic burden), as quantified by various scales, has been associated with adverse outcomes particularly in people with dementia. Anticholinergic medications are routinely reviewed in memory clinic attendees but any attempt to target and reduce anticholinergic burden relies on the methods used to quantify it. This project aimed to evaluate the extent of anticholinergic burden in attendees and to assess agreement between two anticholinergic scales. Methods: A retrospective review of the medical notes of patients seen sequentially in the memory clinic from 1st October 2018 was completed. Anticholinergic burden was estimated using the Anticholinergic Cognitive Burden Scale (ACB) and the Anticholinergic Risk Scale (ARS). The findings of the two scales were compared. Results: Data were available from 104 patients. Age (M = 79, SD = 9.7), gender [male n = 35 (34%)], MMSE score (M = 21, SD = 4.4), dementia or mild cognitive impairment diagnosis [n = 81 (78%)]. 45 (43%) were taking at least one medication with anticholinergic properties. Median anticholinergic burden differed between the two scales ACB 0 (IQR 0-1), ARS 0 (IQR 0-0), p < 0.001 (Wilcoxon signed-rank test). There was a clinically significant difference in those identified as having significant burden ACB 10 (10%), ARS 6 (6%). Key conclusions: Use of medication with anticholinergic properties was common in this group. The two scales did not agree on the degree of cumulative anticholinergic burden. These data highlight the need for an agreed method of quantifying anticholinergic burden, before interventions to reduce it can be developed and tested.
机译：介绍：具有抗胆碱能性质的药物是广泛的用途。通过各种鳞片量化的累积抗胆碱能暴露（抗胆碱能负荷）与患有痴呆症的人的不利结果有关。抗胆碱能药物在记忆诊所与会者中经常审查，但任何靶向和降低抗胆碱能负担的尝试都依赖于用于量化其的方法。该项目旨在评估与会者的抗icholinergic负担的程度，并评估两种抗胆碱能鳞片之间的一致性。方法：完成了2018年10月1日在记忆诊所顺序观察到的患者医疗票据的回顾性审查。使用抗胆碱能认知负荷量表（ACB）和抗胆碱能量尺度（ARS）估算抗胆碱能负担。比较了两种尺度的发现。结果：可从104名患者获得数据。年龄（m = 79，sd = 9.7），性别[雄性n = 35（34％）]，mmse得分（m = 21，sd = 4.4），痴呆或轻度认知障碍诊断[n = 81（78％）] 。 45（43％）患有至少一种具有抗胆碱能性的药物。两种尺度ACB 0（IQR 0-1），ARS 0（IQR 0-0），P <0.001（WILCOXON签名 - 秩检验）之间的中位抗胆碱能负担。鉴定为具有显着负荷ACB 10（10％）的临床上有临床显着差异，ARS 6（6％）。关键结论：在该组中使用用抗胆碱能性质使用药物。两种尺度不达成累积抗胆碱能负担的程度。这些数据突出了对量化抗胆碱能负担的商定方法的需求，在减少它的干预之前可以开发和测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号